CSI Market
Sign In | Register

Jade Biosciences Inc (JBIO) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access JBIO Annual Cash Flow →
Quarterly cash flow trends provide additional context on Jade Biosciences Inc's liquidity and ability to support ongoing operations and capital needs.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-96.13
Depreciation & amortization0.02
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation21.41
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Interest Expense-
Increase Decrease In Operating Lease Asseta And Liability-
Increase Decrease In Operating Lease Asset And Liability-
Change In Fair Value Of Convertible Notes Payable-
Operating Lease Expense0.03
Increase Decrease In Accrued Expenses And Other Current Liabilities Related Parties-4.18
Income taxes0.00
Losses/ -gains on Investments net-0.25
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable4.43
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities5.86
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-2.61
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.85
Payments for (Proceeds from) Other Operating Activities-1.31
Discontinued operations0.00
Net Cash flow from Operating Activities-67.74
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments For Proceeds From Security Deposit-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments-106.10
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-106.10
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock2.16
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net190.56
Cash Acquired In Connection With The Reverse Recapitalization-
Payment Of Deferred Offering Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities192.73
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-67.74
Total Cash Flow18.81
4 historic quarters locked

Sign in to unlock the full Jade Biosciences Inc cash flow history.

Sign In Create Free Account

About Jade Biosciences Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-341242

Figures are derived from filed reports and may be restated. Historical data is subject to revision.